We investigated antibodies to factor VII/VIIa (FVII/VIIa) and five other common target antigens in 33 patients with a history of anti-phospholipid syndrome (APS) and 50 healthy controls using an enzyme-linked immunosorbent assay (ELISA) technique. We found that antibody to FVII/VIIa, a previously unrecognized and common antigen in APS, was present in 67% of patients. Frequencies of antibodies to other target antigens were: anti-beta-2 glycoprotein 1 (anti-beta 2GP1), 88%; anti-cardiolipin (anti-CL), 76%; anti-phosphatidylethanolamine (anti-PE), 67%; anti-phosphatidylserine (anti-PS), 64%; and anti-phosphatidylcholine (anti-PC), 59%. Most patients had antibodies against multiple antigens, but a few were positive for only anti-beta 2GP1 (12%) or anti-CL (3%). Positivity for anti-FVII/VIIa was significantly associated with positivity for anti-PE, anti-PS and/or anti-PC (P < 0.05) but not anti-beta 2GP1. When frequencies of immunoglobulin G (IgG) versus immunoglobulin M (IgM) antibodies were compared, anti-beta 2GP1 IgG correlated with the lupus anticoagulant (P < 0.05) and was significantly more prevalent than IgM, but the reverse was seen for all other antigens. In arterial thrombosis, IgM was more prevalent for all antigens, and was significantly associated with FVII/VIIa, PE and PS, whereas in venous thrombosis, IgG was frequently prevalent, especially in association with FVII/VIIa, beta 2GP1 and CL. In summary, FVII/VIIa is a new and common antigen in APS. Anti-FVII/VIIa is often associated with anti-PE, anti-PS and anti-PC. The IgM class is more frequently associated with arterial thrombosis and the IgG class with venous thrombosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1046/j.1365-2141.2003.04161.x | DOI Listing |
Acta Med Indones
January 2015
Department of Clinical Pathology, Faculty of Medicine, University of Andalas - M. Djamil Hospital, Padang, Indonesia.
Aim: to analyse the effects of immunoglobulin(Ig)G and IgM anti-beta-2 glycoprotein-1 (anti-2GP1) on the expression of tissue factor (TF), thrombomodulin (TM), and plasminogen activator inhibitor-1(PAI-1) of endothelial cells in the messenger RNA level.
Methods: laboratory experimental study in human umbilical vein endothelial cells (HUVEC) was done at Cipto Mangunkusumo Hospital/Faculty of Medicine, Universitas Indonesia. Samples are purified IgG anti-2GP1 from six antiphospholipid syndrome (APS) patients serum and IgM anti-2GP1 from six APS patients serum.
Ann Rheum Dis
March 2008
Department of Rheumatology, Hospital for Special Surgery, New York, USA.
Objective: To investigate the prevalence and clinical correlates of anti-heparin platelet factor 4 antibodies (anti-HPF4) in systemic lupus erythematosus (SLE) patients with and without antiphospholipid antibodies (aPL).
Methods: Sera and clinical data were obtained from the Hospital for Special Surgery Autoimmune Disease Registry for 78 aPL-positive and 91 aPL-negative SLE patients without heparin-induced thrombocytopenia (HIT). Controls were 90 blood donors of comparable age and sex.
Br J Haematol
February 2003
Department of Medicine, University of Miami School of Medicine, Miami, FL 33136, USA.
We investigated antibodies to factor VII/VIIa (FVII/VIIa) and five other common target antigens in 33 patients with a history of anti-phospholipid syndrome (APS) and 50 healthy controls using an enzyme-linked immunosorbent assay (ELISA) technique. We found that antibody to FVII/VIIa, a previously unrecognized and common antigen in APS, was present in 67% of patients. Frequencies of antibodies to other target antigens were: anti-beta-2 glycoprotein 1 (anti-beta 2GP1), 88%; anti-cardiolipin (anti-CL), 76%; anti-phosphatidylethanolamine (anti-PE), 67%; anti-phosphatidylserine (anti-PS), 64%; and anti-phosphatidylcholine (anti-PC), 59%.
View Article and Find Full Text PDFClin Transplant
October 2002
Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555-0178, USA.
Introduction: End stage renal disorder (ESRD) patients with antiphospholipid antibody syndrome (APAS) are at high risk for the development of post-transplant renal thrombosis. Positive titre of anticardiolipin antibodies (ACA) is considered a major characteristic of APAS. However, several studies have suggested that ACA in patients with APAS do not bind to phospholipids alone.
View Article and Find Full Text PDFChin Med J (Engl)
January 1999
Department of Clinical Immunology & Rheumatology, Renji Hospital, Shanghai Second Medical University, Shanghai 200001, China.
Objective: To investigate cloning and expression of beta 2-glycoprotein 1 (beta 2GP1) recognized by antiphospholipid antibodies and to study the clinical significance of anti-beta 2GP1 antibodies in patients with autoimmune disease.
Methods: By using reverse transcription-PCR method, two kinds of expression plasmid which expressed beta 2GP1 and the fifth domain of beta 2-glycoprotein 1 (beta 2GP1-D5) proteins respectively were constructed in this study. Their antigenic activities were identified by immunoblots using rabbit anti-beta 2GP1 antibodies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!